Samuel Merrill, MD
Hematology · Morgantown, WVNPI 1144529769
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,186 of the $14,761 with a category attached, or 89.3%. 5 manufacturers reported payments, led by AstraZeneca at 40.9% of the total.
Across 10 payments — averaging $1476.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Sanofi$6K
- Genentech, Inc.$2K
- Rigel Pharmaceuticals, Inc.$1K
- Bayer$96
Across 7 payments — averaging $8544.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$32K
- Pfizer$28K
What the payments were for
- Consulting fees$13,18689%
- Speaking & faculty fees$1,3509%
- Food & beverage$2252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $6,039 |
| Sanofi | 2 | $5,606 |
| Genentech, Inc. | 1 | $1,820 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,200 |
| Bayer | 1 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DopteletAvatrombopag Maleate | 12 | $151,140 |
| EliquisApixaban | 15 | $8,769 |
| Hydroxyurea | 29 | $592 |
Paid to pharmacies, not to this prescriber.
Other hematology in Morgantown
- Raheel SiddiquiMorgantown$276
- Carlos VasquezWheeling$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.